DOCSLIB.ORG

Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1) Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1) July 7, 2016 11:12 AM ET Interim Efficacy Results and BLA Filing Expected in 2016 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, announced today that it has completed enrollment of 72 patients in DLBCL cohort in the Phase 2 portion of ZUMA-1. KTE-C19 is an investigational therapy in which a patient's T-cells are genetically modified to express a chimeric antigen receptor (CAR) that is designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The DLBCL cohort of ZUMA-1 enrolled patients whose disease is chemorefractory (no response to last line of therapy or has relapsed within 12 month of autologous stem cell therapy). Patients received a lymphodepletion regimen that consisted of "low-dose" chemotherapy regimen of cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily for 3 days prior to infusion of the target KTE-C19 dose of 2 x 106 cells/kg. "We are excited to complete enrollment in our first multi-center KTE-C19 study, an important milestone toward bringing this potential breakthrough therapy to patients with an urgent need for better treatment," said David Chang, M.D., Ph.D., Kite's Executive Vice President, Research and Development, and Chief Medical Officer. "We are grateful to the patients and investigators who participated in our study. We look forward to announcing top-line data from the first 50 DLBCL patients in the ZUMA-1 study, and, subject to these results, plan on submitting our Biologics License Application (BLA) with the U.S. Food and Drug Administration by the end of 2016." About Kite's ZUMA Clinical Programs for KTE-C19 KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a CAR that is designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Study Phase Indication Status ZUMA-1 Phase 2 Pivotal Chemorefractory DLBCL (N=72) Phase 2 enrollment complete NCT02348216 (N=112) PMBCL, TFL (N=40) Phase 2 enrolling ZUMA-2 Phase 2 Pivotal NCT02601313 (N=70) Relapsed/refractory MCL Phase 2 enrolling ZUMA-3 Phase 1/2 Pivotal NCT02614066 (N=75) Relapsed/refractory Adult ALL Phase 1/2 enrolling ZUMA-4 Phase 1/2 Pivotal NCT02625480 (N=75) Relapsed/refractory Pediatric ALL Phase 1/2 enrolling DLBCL = diffuse large B-cell lymphoma PMBCL = primary mediastinal B-cell lymphoma TFL = transformed follicular lymphoma MCL = mantle cell lymphoma ALL = acute lymphoblastic leukemia About Kite Pharma Page 1/2 Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma. Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward- looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability and timing of obtaining interim KTE-C19 data and submitting a BLA with the U.S. Food and Drug Administration for regulatory approval based on the ZUMA-1 study of KTE-C19. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended March 31, 2016. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. View source version on businesswire.com: http://www.businesswire.com/news/home/20160707006494/en/ Kite Pharma Greg Mann VP, Investor Relations [email protected] or For Media: inVentiv Health David Polk, 310-309-1029 [email protected] Source: Kite Pharma, Inc. News Provided by Acquire Media Page 2/2.
Load more

Recommended publications
  • Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor
    Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor To the extentstatements contained in this presentation are not descriptionsof historical facts regarding Kite Pharma, Inc. (“Kite,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward- looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success, cost and timing of our product development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research and development activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19 and any other product candidates; (iv) our ability to obtain funding for our operations and further development and commercialization of our product candidates; (v) our plans to research and discover
    [Show full text]
  • Key Metrics for Recent Technology and Life Sciences Initial Public Offerings
    H1 2014 Key Metrics for Recent Technology and Life Sciences Initial Public Offerings H1 2014 Key Metrics for Recent Technology and Life Sciences Initial Public Offerings H1 2014 Survey Introduction and Background This report has been developed as a resource for our clients and friends interested in understanding recent IPO activity of technology and life sciences companies. This information comprises a number of graphs and charts reflecting selected statistics that we believe provide useful information about activity in these markets. This is followed by the listing of technology and life sciences IPOs priced in the first half of 2014 and second half of 2013. We hope that you find this useful. Please contact Daniel J. Winnike at [email protected] or Jeffrey R. Vetter at [email protected] if you care to discuss this information or, as always, contact members of your client service team for more information. Survey Contents Survey Results ..................................................................................................................................................... 2 Offerings Completed ............................................................................................................................................. 3 Size of Offerings, Red Herring Midpoint ................................................................................................................. 4 Size of Offerings, Final IPO Price ...........................................................................................................................
    [Show full text]
  • Investment Thesis for Kite Pharma, Inc. (Nasdaq: Kite)
    SAF/No.14/March 2017 Studies in Applied Finance INVESTMENT THESIS FOR KITE PHARMA, INC. (NASDAQ: KITE) Samantha Semenkow Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise Investment Thesis for Kite Pharma, Inc. (Nasdaq: KITE) by Samantha Semenkow Investment Thesis for Kite Pharma, Inc. (Nasdaq: KITE) By Samantha Semenkow Disclaimer: These research reports are primarily student reports for academic purposes and are not specific recommendations to buy or sell a stock. Potential investors should consult a qualified investment advisor before making an investment. About the Series The Studies in Applied Finance series is under the direction of Professor Steve H. Hanke ([email protected]), Co-director of The Johns Hopkins Institute for Applied Economics, Global Health, and the Study for Business Enterprise, and Dr. Hesam Motlagh ([email protected]), a Fellow at the Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise. This working paper is one in a series on Applied Financial Economics that focuses on company valuations. The authors are mainly students at The Johns Hopkins University and The Johns Hopkins School of Medicine in Baltimore, MD who have conducted their work at the institute as undergraduate and graduate researchers. About the Author Samantha Semenkow ([email protected]) is a PhD candidate in the Pathobiology Graduate Program at The Johns Hopkins School of Medicine in Baltimore, MD. She conducted the research for this paper while serving as Professor Hanke’s research assistant at The Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise during the Fall of 2016.
    [Show full text]
  • Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
    August 28, 2017 Gilead Sciences to Acquire Kite Pharma for $11.9 Billion -- Immediately Positions Gilead as a Leader in Cell Therapy -- -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU -- -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation -- -- Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs -- FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170828005415/en/ Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S.
    [Show full text]
  • Axelrod V. Kite Pharma, Inc. Et
    Case 2:17-cv-06684 Document 1 Filed 09/11/17 Page 1 of 26 Page ID #:1 1 Rosemary M. Rivas (State Bar No. 209147) Email: [email protected] 2 LEVI & KORSINSKY, LLP 44 Montgomery Street, Suite 650 3 San Francisco, California 94104 Telephone: (415) 291-2420 4 Facsimile: (415) 484-1294 5 Counsel for Plaintiff Merry Axelrod 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE CENTRAL DISTRICT OF CALIFORNIA 10 MERRY AXELROD, individually and on Case No. 2:17-cv-6684 behalf of all others similarly situated, 11 CLASS ACTION Plaintiff, 12 CLASS ACTION COMPLAINT FOR v. VIOLATION OF SECTIONS 14(d)(4), 13 14(e), AND 20(a) OF THE KITE PHARMA, INC., ARIE SECURITIES EXCHANGE ACT OF 14 BELLDEGRUN, DAVID BONDERMAN, 1934 FARAH CHAMPSI, IAN CLARK, ROY 15 DOUMANI, FRANZ HUMER, JOSHUA JURY TRIAL DEMANDED A. KAZAM, RAN NUSSBAUM, JON 16 PEACOCK, STEVEN B. RUCHEFSKY, OWEN N. WITTE, GILEAD SCIENCES, 17 INC., and DODGE MERGER SUB, INC., 18 Defendants. 19 20 Plaintiff Merry Axelrod (“Plaintiff”), by her attorneys, alleges upon information 21 and belief, except for her own acts, which are alleged on knowledge, as follows: 22 INTRODUCTION 23 1. Plaintiff brings this action on behalf of herself and the public stockholders 24 of Kite Pharma, Inc. (“Kite” or the “Company”) against Kite and members of its Board 25 of Directors (collectively, the “Board” or the “Individual Defendants,” as further defined 26 below, and together with the Company “Defendants”) for violations of Section 14(d)(4), 27 15 U.S.C. § 78n(d)(4), of the Securities and Exchange Act of 1934 (the “Exchange Act”), 28 U.S.
    [Show full text]
  • Gene Therapy to Fight a Blood Cancer Succeeds in Major Study Marilynn Marchione, Ap Chief Medical Writer Updated 2:21 Am, Thursday, March 2, 2017
    3/10/2017 Gene therapy to fight a blood cancer succeeds in major study - SFGate http://www.sfgate.com/news/medical/article/Gene-therapy-to-fight-a-blood-cancer-succeeds-in-10964727.php Gene therapy to fight a blood cancer succeeds in major study Marilynn Marchione, Ap Chief Medical Writer Updated 2:21 am, Thursday, March 2, 2017 IMAGE 1 OF 2 In this May 2016 photo provided by Kite Pharma, cell therapy specialists at the company's manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight ... more An experimental gene therapy that turns a patient's own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday. In all, 82 percent of patients had their cancer shrink at least by half at some point in the study. Its sponsor, California-based Kite Pharma, is racing Novartis AG to become the first to win approval of the treatment, called CAR-T cell therapy, in the U.S. It could become the nation's first approved gene therapy. A hopeful sign: the number in complete remission at six months — 36 percent — is barely changed from partial results released after three months, suggesting this one-time treatment might give lasting benefits for those who do respond well. "This seems extraordinary ... extremely encouraging," said one independent expert, Dr. Roy Herbst, cancer medicines chief at the Yale Cancer Center.
    [Show full text]
  • For Immediate Release Pfizer Media Contact: April 3, 2018 Jessica Smith (212) 733-6213 [email protected]
    For immediate release Pfizer Media Contact: April 3, 2018 Jessica Smith (212) 733-6213 [email protected] Pfizer Investor Contact: Chuck Triano (212) 733-3901 [email protected] Allogene Media/Investor Contact: Christine Cassiano (714) 552-0326 [email protected] Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio Creates alliance with Allogene Therapeutics, a biotechnology company co-founded and led by former executives of Kite Pharma that is positioned to expedite the development of allogeneic CAR T cell therapy Allogene Therapeutics, a Two River portfolio company, was formed with one of the largest Series A financings in biotechnology of $300 million from a premier investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer Pfizer will hold a 25 percent ownership stake in Allogene Therapeutics NEW YORK, N.Y. and South San Francisco, Calif., April 3, 2018 – Pfizer Inc. (NYSE: PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapY, an investigational immune cell therapY approach to treating cancer. Allogene, co-founded and led bY former executives of Kite Pharma, is ideallY positioned to catalYze the development of this allogeneic cell therapY portfolio. Arie Belldegrun, M.D., FACS, Founder and former Chairman, President and Chief Executive Officer of Kite, will serve as Executive Chairman, and David Chang, M.D., Ph.D., former Executive Vice President, Research and Development and Chief Medical Officer of Kite, will serve as President and Chief Executive Officer.
    [Show full text]
  • Rapid Tumor Regression from PD-1 Inhibition After Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Diffuse Large B-Cell Lymphoma
    Bone Marrow Transplantation (2020) 55:1184–1187 https://doi.org/10.1038/s41409-019-0657-3 CORRESPONDENCE Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma 1 2 2 2 1,3 Brian T. Hill ● Zachary J. Roberts ● Allen Xue ● John M. Rossi ● Mitchell R. Smith Received: 24 January 2019 / Revised: 7 June 2019 / Accepted: 30 June 2019 / Published online: 30 August 2019 © Springer Nature Limited 2019. This article is published with open access To the Editor: large B-cell lymphoma (DLBCL), with strong PD-L1 expression, whose disease did not respond to axi-cel but Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 who experienced rapid tumor regression after receiving sub- chimeric antigen receptor (CAR) T-cell therapy approved by sequent anti-PD-1 therapy. the US Food and Drug Administration for adult patients with ZUMA-1 (NCT02348216) is a multicenter, phase 1/ relapsed/refractory large B-cell lymphoma after ≥2 lines of 2 study of axi‑cel in patients with refractory large B-cell 1234567890();,: 1234567890();,: systemic therapy [1, 2]. In ZUMA-1, the pivotal study of axi- lymphoma [3, 8, 9]. After leukapheresis and manufacturing, cel in refractory large B-cell lymphoma, with a median of patients received low-dose conditioning chemotherapy 27.1 months follow-up, the objective response rate was 83%, (cyclophosphamide 500 mg/m2 and fludarabine 30 mg/m2 including 58% complete responses [3]. Grade ≥3 cytokine intravenously, days −5to−3) and a single intravenous axi- release syndrome (CRS) and neurologic events occurred in cel infusion (target dose, 2 × 106 CAR T cells/kg, day 0).
    [Show full text]
  • Kite Pharma Initiates Phase 1B/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) October 6, 2016 10:15 AM ET First patient enrolled in ZUMA-6 study evaluating safety and efficacy of anti-CD19 CAR (KTE-C19) therapy in combination with anti-PD-L1 monoclonal antibody atezolizumab SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech's anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma (DLBCL). PD-L1 expression in DLBCL is associated with high-risk disease and poor outcomes. The interaction of PD-L1 and PD-1, which is expressed on KTE-C19, may dampen T-cell activity in some patients. As a result, use of the two compounds in combination could provide a synergistic effect since inhibiting PD-L1 with atezolizumab may enhance and prolong the activity and proliferation of KTE-C19. "The ZUMA-6 combination study is a core element of our broad strategy to optimize KTE-C19 treatment outcomes and to significantly extend the important potential benefits of KTE-C19 monotherapy," said David Chang, M.D., Ph.D., Kite's Executive Vice President, Research and Development, and Chief Medical Officer. "We view the scientific rationale for this combination study as compelling and look forward to advancing the study based on our extensive clinical experience." Kite entered a clinical collaboration in March 2016 with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of KTE-C19 in combination with atezolizumab.
    [Show full text]
  • The Cancer Immunotherapy Pilot Program and Chimeric Antigen Receptor-T Cell Treatments
    Boston College Intellectual Property and Technology Forum http://bciptf.org THE CANCER IMMUNOTHERAPY PILOT PROGRAM AND CHIMERIC ANTIGEN RECEPTOR-T CELL TREATMENTS ELLEN SHAMANSKY Abstract: The Cancer Immunotherapy Pilot Program (also known as Patents 4 Patients) provides fast-track review to patent applications describing methods of treating cancer with immunotherapy, such as chimeric antigen receptor (“CAR”)- T cell treatments. This article explores considerations for claiming CAR-T cell treatments, including court rulings and examiner guidelines on patentable subject matter in the life sciences, the Federal Circuit’s decision in NantKwest, Inc. v. Lee in 2017, and pending applications and current litigation over CAR-T cell treatments. I. INTRODUCTION Cancer immunotherapy refers to biological treatments that use the immune system to combat cancer.1 These treatments, including monoclonal antibodies, antibody drug conjugates, cancer treatment vaccines, bacillus Calmette-Guérin therapy, gene therapy, and adoptive T-cell transfer therapy, take many approaches and have a variety of mechanisms of action.2 A point of commonality, however, is that all require more complicated production schemes than those used to manufacture small molecule drugs.3 Also, because biological treatments are living organisms, such as bacteria and viruses, or substances derived from living organisms, such as antibodies of the immune system, they 1 Biological Therapies for Cancer, NAT’L CANCER INST., https://www.cancer.gov/about- cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet (last visited Apr. 26, 2018). 2 Id.; Game Changers: How CAR-T and Cell Therapy Are Revolutionizing Cancer Immunotherapy, FOLEY & LARDNER LLP (Dec. 7, 2017), https://www.foley.com/game- changers-how-car-t-and-cell-therapy-are-revolutionizing-cancer-immunotherapy-12-07- 2017/ [hereinafter Game Changers].
    [Show full text]
  • Kite Pharma and the Leukemia & Lymphoma
    Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs July 1, 2015 4:15 PM ET SANTA MONICA, Calif. and WHITE PLAINS, N.Y., July 1, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. Under the collaboration, LLS will launch a broad scope educational program focusing on CAR T-cell therapy for the treatment of blood cancers, as well as support outreach for clinical trial enrollment. LLS also will contribute up to $2.5 million, through the Therapy Acceleration Program (TAP), to help fund Kite's ongoing Phase 1/2 clinical study of KTE-C19 (see ClinicalTrials.gov, using Identifier NCT: 02348216), which is designed to evaluate safety and efficacy in the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), as well as two rare lymphomas - primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). Based on the progress of the program, Kite will make certain milestone payments to LLS and provide financial support to LLS for its rollout of the education program.
    [Show full text]
  • Kite Pharma Announces Patients with Aggressive Non-Hodgkin's
    Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI) August 25, 2014 11:23 AM ET Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI) Phase 1-2a Clinical Trial Highlights: 12 of 13 Total Evaluable Patients with Advanced B Cell Malignancies Had Complete Remissions (8 Patients) or Partial Remissions (4 Patients) Resulting in a 92% Objective Response Rate 4 of 7 Evaluable Patients with Chemotherapy-Refractory Diffuse Large B-cell Lymphoma (DLBCL) Achieved Complete Remissions, 3 of Which Are Ongoing and 1 of Which Is Ongoing after 22 Months The Results Have Been Published in the August 25, 2014 Issue of the American Society of Clinical Oncology's (ASCO) Journal of Clinical Oncology The Results Support Kite's Plan to File an Investigational New Drug Application (IND) in the Fourth Quarter of 2014 to Initiate a Clinical Trial of Kite's Lead CAR-Based Product Candidate, KTE-C19, in Patients with DLBCL SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.
    [Show full text]